New gel treatment for Parkinson's aims to reduce 'Off' time

NCT ID NCT07313176

Recruiting now Disease control Sponsor: Britannia Pharmaceuticals Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 215 adults with advanced Parkinson's disease who are switching from a pump medication to a new intestinal gel called LECIGON®. Researchers want to see if the gel reduces daily 'off' time—when symptoms return—over 12 months. Participants continue their usual care while doctors track changes using a standard rating scale.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

movement disorder neurodegenerative disease Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PARKINSON DISEASE

Contacts and locations

Locations

Complejo Hospitalario Universitario de A Coruña (CHUAC)
RECRUITING

A Coruña, A Coruña, 15006, Spain
Hospital Universitario de Toledo
RECRUITING

Toledo, Castille-La Mancha, 45007, Spain
Hospital de Basurto
RECRUITING

Bilbao, Vizcaya, 48013, Spain
Hospital de Cruces
RECRUITING

Barakaldo, Vizcaya, 48903, Spain
Virgen del Rocío University Hospital
RECRUITING

Seville, Av. Manuel Siurot, S/n, 41013, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.